Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
cancer
11
×
life sciences
national blog main
national top stories
san francisco blog main
san francisco top stories
11
×
biotech
indiana blog main
indiana top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
clinical trials
deals
eli lilly
investing
roche
startups
cancer immunotherapy
fda
merck
novartis
pfizer
abbvie
What
drug
11
×
roundup
bio
cancer
fda
companies
new
alzheimer’s
annual
approval
approved
attention
biotech
genetic
latest
market
medicine
medicines
nash
news
patients
plan
price
prices
research
targets
week
acquisitions
address
advantages
ahead
ambien
american
approves
asco
assessed
attendees
bar
biggest
biogen’s
Language
unset
Current search:
cancer
×
drug
×
" san francisco top stories "
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
6 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More